Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
When to choose an index fund depends on costs, diversification needs, and your time horizon; use these criteria to guide selection.
14,060 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
As Berkshire Hathaway prepares for a new era, Warren Buffett successor Greg Abel may be quietly orchestrating a bold,...
USO has surged nearly 100% this year as Hormuz shutdowns persisted. A reopening could spark a swift unwind.
In a rare private hour-long session, Senator Bernie Sanders pressed for public ownership of AI firms, while OpenAI ch...
AAI disruption is reshaping markets, and Nvidia sits at the center. This piece breaks down how billionaires instituti...
In a Dallas suburb, a late-career couple tests whether a one-income plan can support a dream of full-time writing whi...
Savers weigh where to park cash as rates shift. High yield savings accounts offer liquidity and FDIC protection with ...
A year into UVXY's latest cycle, a $10,000 stake has fallen far beyond typical market moves. The fund's mechanics hav...
When Netflix drops its biggest series debut of 2026, millions tune in. The real lesson isn’t just about TV—it's about...
Public family disputes can ripple through a household’s finances. This feature explains the money side of a high-prof...
As July 2026 unfolds, the two JPMorgan income ETFs clash over safety versus yield. This piece weighs performance, pay...
Money troubles can hit anyone, even a former star le’veon bell. This article digs into what happened, why it matters ...